共识报告:粪便微生物移植--临床应用与处理 2017年

2017-01-02 Aliment Pharmacol Ther. 2017 Jan;45(2):222-239

BACKGROUND:Faecal microbiota transplantation or transfer (FMT) aims at replacing or reinforcing the gut microbiota of a patient with the microbiota from a healthy donor. Not many controlled or randomi

中文标题:

共识报告:粪便微生物移植--临床应用与处理 2017年

英文标题:

Consensus report: faecal microbiota transfer - clinical applications and procedures.

发布机构:

发布日期:

2017-01-02

简要介绍:

BACKGROUND:

Faecal microbiota transplantation or transfer (FMT) aims at replacing or reinforcing the gut microbiota of a patient with the microbiota from a healthy donor. Not many controlled or randomised studies have been published evaluating the use of FMT for other diseases than Clostridium difficile infection, making it difficult for clinicians to decide on a suitable indication.

AIM:

To provide an expert consensus on current clinical indications, applications and methodological aspects of FMT.

METHODS:

Well-acknowledged experts from various countries in Europe have contributed to this article. After literature review, consensus has been achieved by repetitive circulation of the statements and the full manuscript among all authors with intermittent adaptation to comments (using a modified Delphi process). Levels of evidence and agreement were rated according to the GRADE system. Consensus was defined a priori as agreement by at least 75% of the authors.

RESULTS:

Key recommendations include the use of FMT in recurrent C. difficile infection characterised by at least two previous standard treatments without persistent cure, as well as its consideration in severe and severe-complicated C. difficile infection as an alternative to total colectomy in case of early failure of antimicrobial therapy. FMT in inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS) and metabolic syndrome should only be performed in research settings.

CONCLUSIONS:

Faecal microbiota transplantation or transfer is a promising treatment for a variety of diseases in which the intestinal microbiota is disturbed. For indications other than C. difficile infection, more evidence is needed before more concrete recommendations can be made.

相关资料下载:
[AttachmentFileName(sort=100, fileName=共识报告:粪便微生物移植--临床应用与处理 2017年)] GetToolGuiderByIdResponse(projectId=1, id=c5b521c0013a684f, title=共识报告:粪便微生物移植--临床应用与处理 2017年, enTitle=Consensus report: faecal microbiota transfer - clinical applications and procedures., guiderFrom=Aliment Pharmacol Ther. 2017 Jan;45(2):222-239, authorId=null, author=, summary=BACKGROUND:Faecal microbiota transplantation or transfer (FMT) aims at replacing or reinforcing the gut microbiota of a patient with the microbiota from a healthy donor. Not many controlled or randomi, cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Mon Jan 02 18:18:40 CST 2017, originalUrl=, linkOutUrl=, content=<h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif; line-height: 19.994px;">BACKGROUND:</h4><p style="margin: 0px 0px 0.5em; font-size: 1.04em; font-family: arial, helvetica, clean, sans-serif; line-height: 19.994px;"><abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">Faecal microbiota transplantation or transfer (FMT) aims at replacing or reinforcing the gut microbiota of a patient with the microbiota from a healthy donor. Not many controlled or randomised studies have been published evaluating the use of FMT for other diseases than Clostridium difficile infection, making it difficult for clinicians to decide on a suitable indication.</abstracttext></p><h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif; line-height: 19.994px;">AIM:</h4><p style="margin: 0px 0px 0.5em; font-size: 1.04em; font-family: arial, helvetica, clean, sans-serif; line-height: 19.994px;"><abstracttext label="AIM" nlmcategory="OBJECTIVE">To provide an expert consensus on current clinical indications, applications and methodological aspects of FMT.</abstracttext></p><h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif; line-height: 19.994px;">METHODS:</h4><p style="margin: 0px 0px 0.5em; font-size: 1.04em; font-family: arial, helvetica, clean, sans-serif; line-height: 19.994px;"><abstracttext label="METHODS" nlmcategory="METHODS">Well-acknowledged experts from various countries in Europe have contributed to this article. After literature review, consensus has been achieved by repetitive circulation of the statements and the full manuscript among all authors with intermittent adaptation to comments (using a modified Delphi process). Levels of evidence and agreement were rated according to the GRADE system. Consensus was defined a priori as agreement by at least 75% of the authors.</abstracttext></p><h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif; line-height: 19.994px;">RESULTS:</h4><p style="margin: 0px 0px 0.5em; font-size: 1.04em; font-family: arial, helvetica, clean, sans-serif; line-height: 19.994px;"><abstracttext label="RESULTS" nlmcategory="RESULTS">Key recommendations include the use of FMT in recurrent C. difficile infection characterised by at least two previous standard treatments without persistent cure, as well as its consideration in severe and severe-complicated C. difficile infection as an alternative to total colectomy in case of early failure of antimicrobial therapy. FMT in inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS) and metabolic syndrome should only be performed in research settings.</abstracttext></p><h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif; line-height: 19.994px;">CONCLUSIONS:</h4><p style="margin: 0px 0px 0.5em; font-size: 1.04em; font-family: arial, helvetica, clean, sans-serif; line-height: 19.994px;"><abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">Faecal microbiota transplantation or transfer is a promising treatment for a variety of diseases in which the intestinal microbiota is disturbed. For indications other than C. difficile infection, more evidence is needed before more concrete recommendations can be made.</abstracttext></p>, tagList=[TagDto(tagId=33568, tagName=粪便微生物)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2835, appHits=233, showAppHits=0, pcHits=2160, showPcHits=713, likes=127, shares=4, comments=6, approvalStatus=1, publishedTime=Mon Jan 02 18:18:40 CST 2017, publishedTimeString=2017-01-02, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=fbzhang, createdTime=Mon Jan 02 18:18:40 CST 2017, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 00:06:39 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=共识报告:粪便微生物移植--临床应用与处理 2017年)])
共识报告:粪便微生物移植--临床应用与处理 2017年
下载请点击:
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=171006, encodeId=db3b1e100692, content=可惜没有中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/7kIFI7uC0VoJpgU2UgfE067icB8Xr81hNJPe9dJagcthu8iaHPghU7eQmk1yiaEWvcYtGBibcTU4vfB1AqCsj7ax1g/132, createdBy=6c972001305, createdName=宜宾肖, createdTime=Wed Jan 18 01:07:56 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=168779, encodeId=b4a8168e795a, content=好东西学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Jan 08 09:25:15 CST 2017, time=2017-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167938, encodeId=31be16e938a9, content=学习啦,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/31/60fc0213ae09a3dbbba19993663ef4db.jpg, createdBy=33c31971480, createdName=1e160a78m83(暂无匿称), createdTime=Wed Jan 04 15:26:54 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167818, encodeId=788416e81864, content=好东西学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Jan 04 07:08:34 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167767, encodeId=aa6e16e767e4, content=学习啦,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/31/60fc0213ae09a3dbbba19993663ef4db.jpg, createdBy=33c31971480, createdName=1e160a78m83(暂无匿称), createdTime=Tue Jan 03 22:40:34 CST 2017, time=2017-01-03, status=1, ipAttribution=)]
    2017-01-18 宜宾肖

    可惜没有中文版

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=171006, encodeId=db3b1e100692, content=可惜没有中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/7kIFI7uC0VoJpgU2UgfE067icB8Xr81hNJPe9dJagcthu8iaHPghU7eQmk1yiaEWvcYtGBibcTU4vfB1AqCsj7ax1g/132, createdBy=6c972001305, createdName=宜宾肖, createdTime=Wed Jan 18 01:07:56 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=168779, encodeId=b4a8168e795a, content=好东西学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Jan 08 09:25:15 CST 2017, time=2017-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167938, encodeId=31be16e938a9, content=学习啦,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/31/60fc0213ae09a3dbbba19993663ef4db.jpg, createdBy=33c31971480, createdName=1e160a78m83(暂无匿称), createdTime=Wed Jan 04 15:26:54 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167818, encodeId=788416e81864, content=好东西学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Jan 04 07:08:34 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167767, encodeId=aa6e16e767e4, content=学习啦,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/31/60fc0213ae09a3dbbba19993663ef4db.jpg, createdBy=33c31971480, createdName=1e160a78m83(暂无匿称), createdTime=Tue Jan 03 22:40:34 CST 2017, time=2017-01-03, status=1, ipAttribution=)]
    2017-01-08 thlabcde

    好东西学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=171006, encodeId=db3b1e100692, content=可惜没有中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/7kIFI7uC0VoJpgU2UgfE067icB8Xr81hNJPe9dJagcthu8iaHPghU7eQmk1yiaEWvcYtGBibcTU4vfB1AqCsj7ax1g/132, createdBy=6c972001305, createdName=宜宾肖, createdTime=Wed Jan 18 01:07:56 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=168779, encodeId=b4a8168e795a, content=好东西学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Jan 08 09:25:15 CST 2017, time=2017-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167938, encodeId=31be16e938a9, content=学习啦,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/31/60fc0213ae09a3dbbba19993663ef4db.jpg, createdBy=33c31971480, createdName=1e160a78m83(暂无匿称), createdTime=Wed Jan 04 15:26:54 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167818, encodeId=788416e81864, content=好东西学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Jan 04 07:08:34 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167767, encodeId=aa6e16e767e4, content=学习啦,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/31/60fc0213ae09a3dbbba19993663ef4db.jpg, createdBy=33c31971480, createdName=1e160a78m83(暂无匿称), createdTime=Tue Jan 03 22:40:34 CST 2017, time=2017-01-03, status=1, ipAttribution=)]
    2017-01-04 1e160a78m83(暂无匿称)

    学习啦,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=171006, encodeId=db3b1e100692, content=可惜没有中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/7kIFI7uC0VoJpgU2UgfE067icB8Xr81hNJPe9dJagcthu8iaHPghU7eQmk1yiaEWvcYtGBibcTU4vfB1AqCsj7ax1g/132, createdBy=6c972001305, createdName=宜宾肖, createdTime=Wed Jan 18 01:07:56 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=168779, encodeId=b4a8168e795a, content=好东西学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Jan 08 09:25:15 CST 2017, time=2017-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167938, encodeId=31be16e938a9, content=学习啦,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/31/60fc0213ae09a3dbbba19993663ef4db.jpg, createdBy=33c31971480, createdName=1e160a78m83(暂无匿称), createdTime=Wed Jan 04 15:26:54 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167818, encodeId=788416e81864, content=好东西学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Jan 04 07:08:34 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167767, encodeId=aa6e16e767e4, content=学习啦,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/31/60fc0213ae09a3dbbba19993663ef4db.jpg, createdBy=33c31971480, createdName=1e160a78m83(暂无匿称), createdTime=Tue Jan 03 22:40:34 CST 2017, time=2017-01-03, status=1, ipAttribution=)]
    2017-01-04 thlabcde

    好东西学习了!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=171006, encodeId=db3b1e100692, content=可惜没有中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/7kIFI7uC0VoJpgU2UgfE067icB8Xr81hNJPe9dJagcthu8iaHPghU7eQmk1yiaEWvcYtGBibcTU4vfB1AqCsj7ax1g/132, createdBy=6c972001305, createdName=宜宾肖, createdTime=Wed Jan 18 01:07:56 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=168779, encodeId=b4a8168e795a, content=好东西学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Jan 08 09:25:15 CST 2017, time=2017-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167938, encodeId=31be16e938a9, content=学习啦,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/31/60fc0213ae09a3dbbba19993663ef4db.jpg, createdBy=33c31971480, createdName=1e160a78m83(暂无匿称), createdTime=Wed Jan 04 15:26:54 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167818, encodeId=788416e81864, content=好东西学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Jan 04 07:08:34 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167767, encodeId=aa6e16e767e4, content=学习啦,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/31/60fc0213ae09a3dbbba19993663ef4db.jpg, createdBy=33c31971480, createdName=1e160a78m83(暂无匿称), createdTime=Tue Jan 03 22:40:34 CST 2017, time=2017-01-03, status=1, ipAttribution=)]
    2017-01-03 1e160a78m83(暂无匿称)

    学习啦,谢谢分享

    0